320: Jim Wilson's next venture, a surprise startup shutdown, & Lilly's Zepbound strategy

In this engaging discussion, gene therapy pioneer Jim Wilson, known for his groundbreaking work at the University of Pennsylvania, shares insights on his recent departure and future plans. Joining him is Jonathan Wosen, a biotech reporter, who sheds light on the surprising closure of a gene editing company and the challenges facing the industry. They explore Eli Lilly's new pricing strategy for its obesity drug, Zepbound, and the shift toward direct-to-consumer sales. The conversation captures the dynamic, often unpredictable nature of biotech today.